AC Immune

ACIU NASDAQ
5.31
-0.27
-4.84%
Closed 16:00 08/23 EDT
Open
5.57
Prev Close
5.58
High
5.64
Low
5.28
Volume
73.48K
Avg Vol (3M)
96.88K
52 Week High
12.50
52 Week Low
3.250
% Turnover
0.11%
Market Cap
358.76M
1D
5D
1M
3M
1Y
5Y

Company Profile

AC Immune SA is a Switzerland-based clinical-stage biopharmaceutical company. The Company focuses on precision medicine for neurodegenerative diseases. It designs, discovers and develops therapeutic, as well as diagnostic products for prevention, diagnosis and treatment of diseases caused by misfolding proteins. Its SupraAntigen and Morphomer technology platforms to create antibodies, small molecules and vaccines designed to address a broad range of neurodegenerative indications, such as Alzheimer's disease (AD). The Company's pipeline includes nine therapeutic product candidates with five in clinical trials, and three diagnostic candidates. Its lead product candidate is Crenezumab, a humanized and monoclonal anti-Abeta antibody for Alzheimer’s disease. It has collaborations with pharmaceutical companies, including Roche/Genentech, Eli Lilly, Biogen, Janssen Pharmaceuticals, Nestle Institute of Health Sciences, Life Molecular Imaging (formerly Piramal Imaging) and Essex Bio-Technology.
MORE >

Recently

Name
Price
%Change